Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) have been assigned an average rating of “Moderate Buy” from the fifteen analysts that are presently covering the stock, MarketBeat Ratings reports. Four analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. The average twelve-month target price among brokers that have covered the stock in the last year is $173.07.

JAZZ has been the subject of a number of research reports. Morgan Stanley decreased their target price on shares of Jazz Pharmaceuticals from $160.00 to $150.00 and set an “equal weight” rating for the company in a research report on Friday, July 12th. Needham & Company LLC decreased their target price on shares of Jazz Pharmaceuticals from $208.00 to $205.00 and set a “buy” rating for the company in a research report on Thursday, August 1st. The Goldman Sachs Group initiated coverage on shares of Jazz Pharmaceuticals in a research report on Wednesday, June 5th. They issued a “buy” rating and a $169.00 price objective for the company. JPMorgan Chase & Co. upped their price objective on shares of Jazz Pharmaceuticals from $190.00 to $202.00 and gave the stock an “overweight” rating in a research report on Monday, August 19th. Finally, UBS Group decreased their price objective on shares of Jazz Pharmaceuticals from $117.00 to $113.00 and set a “neutral” rating for the company in a research report on Tuesday, July 2nd.

Jazz Pharmaceuticals Trading Up 0.3 %

NASDAQ JAZZ opened at $115.98 on Friday. The company has a market capitalization of $7.31 billion, a PE ratio of 23.91, a P/E/G ratio of 1.76 and a beta of 0.58. The company has a fifty day moving average of $109.54 and a 200 day moving average of $112.86. Jazz Pharmaceuticals has a 1 year low of $99.06 and a 1 year high of $146.70. The company has a debt-to-equity ratio of 1.36, a current ratio of 2.37 and a quick ratio of 1.90.

Institutional Trading of Jazz Pharmaceuticals

Several large investors have recently bought and sold shares of JAZZ. Rise Advisors LLC lifted its holdings in Jazz Pharmaceuticals by 2,255.6% during the 1st quarter. Rise Advisors LLC now owns 212 shares of the specialty pharmaceutical company’s stock worth $26,000 after buying an additional 203 shares in the last quarter. Versant Capital Management Inc raised its holdings in shares of Jazz Pharmaceuticals by 13,450.0% in the 2nd quarter. Versant Capital Management Inc now owns 271 shares of the specialty pharmaceutical company’s stock valued at $29,000 after purchasing an additional 269 shares in the last quarter. Itau Unibanco Holding S.A. acquired a new stake in shares of Jazz Pharmaceuticals in the 2nd quarter valued at $29,000. EverSource Wealth Advisors LLC raised its holdings in shares of Jazz Pharmaceuticals by 55.1% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 273 shares of the specialty pharmaceutical company’s stock valued at $30,000 after purchasing an additional 97 shares in the last quarter. Finally, GAMMA Investing LLC grew its position in shares of Jazz Pharmaceuticals by 65.5% in the 2nd quarter. GAMMA Investing LLC now owns 293 shares of the specialty pharmaceutical company’s stock valued at $31,000 after buying an additional 116 shares during the last quarter. Hedge funds and other institutional investors own 89.14% of the company’s stock.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.